Venetoclax Add-On Improves Complete Remission in AML

A phase 2 study found 91% complete remission in patients with AML who received venetoclax plus standard therapy. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/968484?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost